260 Results

People

  1. Motzer
    Motzer
  2. Baselga
    Baselga
  3. Seidman
    Seidman
  4. Hudis
    Hudis
  5. Ilson
    Ilson
  6. O'Reilly
    O'Reilly
  7. Zelenetz
    Zelenetz
  8. Aghajanian
    Aghajanian
  9. Bajorin
    Bajorin
  10. Schwartz
    Schwartz

Groups

  1. Department of Medicine (207)
  2. Solid Tumor Oncology Division (174)
  3. Genitourinary Oncology Service (58)
  4. Breast Medicine Service (37)
  5. Hematologic Malignancies, Division of (34)
  6. Gastrointestinal Oncology Service (31)
  7. Survivorship Research (28)
  8. Center for Hematologic Malignancies (27)
  9. Gynecologic Medicine Service (22)
  10. Thoracic Oncology (20)
  1. "asthenia"
Formats
  1. Journal Article (251)
  2. Review (7)
  3. Conference Paper (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (207)
  2. Solid Tumor Oncology Division (174)
  3. Genitourinary Oncology Service (58)
  4. Breast Medicine Service (37)
  5. Hematologic Malignancies, Division of (34)
  6. Gastrointestinal Oncology Service (31)

More Groups

People
  1. Robert Motzer (38)
  2. Jose Baselga (13)
  3. Andrew Seidman (10)
  4. Clifford Hudis (9)
  5. David Ilson (9)
  6. Eileen O'Reilly (9)

More People

Years
  1. 2025 (8)
  2. 2024 (19)
  3. 2023 (13)
  4. 2022 (8)
  5. 2021 (12)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (24)
  2. Lancet Oncology (24)
  3. Annals of Oncology (15)
  4. Clinical Cancer Research (13)
  5. European Journal of Cancer (9)
  6. New England Journal of Medicine (9)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Elsevier Science, Inc. (39)
  3. American Society of Clinical Oncology (26)
  4. Oxford University Press (25)
  5. Nature Publishing Group (17)
  6. Springer (15)

More Publishers

Results (260)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: The FORT-2 phase 1b nonrandomized clinical trial
    Journal Article

    Sweis, R. F.; Gajate, P.; Morales-Barrera, R.; Lee, J. L.; Necchi, A.; De Braud, F.; Penel, N.; Grünwald, V.; Maruzzo, M.; Meran, J.; more...
    JAMA Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed/refractory hematologic malignancies
    Journal Article

    Desai, P.; Lonial, S.; Cashen, A.; Kamdar, M.; Flinn, I.; O'Brien, S.; Garcia, J. S.; Korde, N.; Moslehi, J.; Wey, M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
    Journal Article

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    Journal Article

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
    Journal Article

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; Jiménez, J. L.; Bishton, M.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    HemaSphere (2024)

    Fulltext@MSK | Save
  • Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
    Journal Article

    Makker, V.; Perez-Fidalgo, J. A.; Valabrega, G.; Hamilton, E.; Van Gorp, T.; Sehouli, J.; Regináčová, K.; Richardson, D. L.; Perri, T.; Oza, A. M.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
    Journal Article

    Valabrega, G.; Pothuri, B.; Oaknin, A.; Graybill, W. S.; Sánchez, A. B.; McCormick, C.; Baurain, J. F.; Tinker, A. V.; Denys, H.; O'Cearbhaill, R. E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: Results of two multi-institutional Phase 1 trials
    Journal Article

    Segal, N. H.; Melero, I.; Moreno, V.; Steeghs, N.; Marabelle, A.; Rohrberg, K.; Rodriguez-Ruiz, M. E.; Eder, J. P.; Eng, C.; Manji, G. A.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: Phase 1 trial interim results
    Journal Article

    Rappaport, A. R.; Kyi, C.; Lane, M.; Hart, M. G.; Johnson, M. L.; Henick, B. S.; Liao, C. Y.; Mahipal, A.; Shergill, A.; Spira, A. I.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Treatment for first cytomegalovirus infection post–hematopoietic cell transplant in the AURORA trial: A multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir
    Journal Article

    Papanicolaou, G. A.; Avery, R. K.; Cordonnier, C.; Duarte, R. F.; Haider, S.; Maertens, J.; Peggs, K. S.; Solano, C.; Young, J. A. H.; Fournier, M.; more...
    Clinical Infectious Diseases (2024)

    Fulltext@MSK | Save